US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

13.15

+0.15001.15%

Post-market: 13.150.00000.00%16:28 EDT

Volume:327.55K

Turnover:4.29M

Market Cap:609.87M

PE:-2.60

High:13.45

Open:13.08

Low:12.66

Close:13.00

52wk High:40.43

52wk Low:9.10

Shares:46.38M

Float Shares:13.40M

Volume Ratio:0.68

T/O Rate:2.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0580

EPS(LYR):-18.5643

ROE:-111.55%

ROA:-67.11%

PB:1.75

PE(LYR):-0.71

Loading ...

Overview Company News Filings

MapLight Therapeutics price target lowered to $24 from $43 at Canaccord

MapLight downgraded to Equal Weight from Overweight at Morgan Stanley

MapLight Therapeutics is Maintained at Buy by HC Wainwright & Co.

U.S. Research Roundup- BioLife Solutions, Gossamer Bio, Intuit

Maplight Therapeutics Inc : Jefferies Cuts Target Price to $25 from $34

THOMSON REUTERS

Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)

MapLight's Schizophrenia Drug Fails Once-daily Test, Shares Plunge

Maplight Therapeutics Shares Drop 55.7% Premarket After Co Announces Mid-Stage Trial Results for Schizophrenia Drug

THOMSON REUTERS

Top Premarket Decliners

MT Newswires Live

MapLight Therapeutics announces topline results from ZEPHYR trial

MapLight Says Phase 2 Zephyr Trial Shows Ml-007c-ma Cuts PANSS Score in Schizophrenia

Maplight Therapeutics - to Proceed with Additional Registrational Trial and Engage FDA at End-of-Phase 2

THOMSON REUTERS

Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint

THOMSON REUTERS

Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia

THOMSON REUTERS

Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events

THOMSON REUTERS

Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial

THOMSON REUTERS

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus

Simply Wall St.

MapLight Therapeutics price target raised to $43 from $35 at Canaccord

U.S. Research Roundup-deckers Brands, Rollins, United Rentals

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/MPLT/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":13.15,"timestamp":1789416000000,"preClose":13,"halted":0,"volume":327550,"hourTrading":{"tag":"盘后","latestPrice":13.15,"preClose":13.15,"latestTime":"16:28 EDT","volume":19574,"amount":257404.07007,"timestamp":1789417718337,"change":0,"changeRate":0,"amplitude":0.003042},"delay":0,"changeRate":0.011538461538461565,"floatShares":13402700,"shares":46377800,"eps":-5.058,"marketStatus":"Post-Mkt","change":0.15,"latestTime":"09-14 17:50:06 EDT","open":13.08,"high":13.45,"low":12.66,"amount":4294239,"amplitude":0.060769,"askPrice":14,"askSize":44,"bidPrice":11.46,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":13,"preHourTrading":{"tag":"盘前","latestPrice":13.05,"preClose":13,"latestTime":"09:29 EDT","volume":2,"amount":26.1,"timestamp":1789392599987,"change":0.05,"changeRate":0.003846,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":13.15,"preClose":13.15,"latestTime":"16:28 EDT","volume":19574,"amount":257404.07007,"timestamp":1789417718337,"change":0,"changeRate":0,"amplitude":0.003042},"volumeRatio":0.681216,"impliedVol":1.1132,"impliedVolPercentile":0.4189},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":13402700,"roa":"-67.11%","roe":"-111.55%","lyrEps":-18.564313,"volumeRatio":0.681216,"shares":46377800,"dividePrice":0,"high":13.45,"amplitude":0.060769,"preClose":13,"low":12.66,"week52Low":9.1,"pbRate":"1.75","week52High":40.43,"institutionHeld":0,"latestPrice":13.15,"committee":0.388889,"eps":-5.058,"divideRate":0,"volume":327550,"delay":0,"ttmEps":-5.058,"open":13.08,"prevYearClose":17.565,"prevWeekClose":13,"prevMonthClose":12.97,"prevQuarterClose":35.84,"fiveDayClose":13.77,"twentyDayClose":11.75,"sixtyDayClose":29.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MPLT","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-05-14","symbol":"MPLT","fiscalQuarterEnding":"2026/03","expectedEps":-0.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-1.34},{"market":"US","date":"2026-03-26","symbol":"MPLT","fiscalQuarterEnding":"2025/12","expectedEps":-1.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-2.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3571,"buy":0.5,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-09-11","current":-2.576117,"percent":0.862385,"low":-9.047313,"twenty":-8.052399,"median":-7.329236,"eighty":-6.1487,"high":-2.251599,"avg":-6.75607,"sd":1.803722,"marketCap":766111286},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-13","current":-7.308017,"twenty":-7.988887,"median":-7.547968,"eighty":-7.020967,"marketCap":751505286},{"date":"2026-02-20","current":-7.605091,"twenty":-7.988887,"median":-7.532944,"eighty":-7.096512,"marketCap":782054282},{"date":"2026-02-27","current":-7.392895,"twenty":-7.98511,"median":-7.541432,"eighty":-7.116712,"marketCap":760233571},{"date":"2026-03-06","current":-7.622066,"twenty":-7.966096,"median":-7.547968,"eighty":-7.127226,"marketCap":783799939},{"date":"2026-03-13","current":-8.122848,"twenty":-7.991064,"median":-7.592359,"eighty":-7.180699,"marketCap":835296817},{"date":"2026-03-20","current":-7.422602,"twenty":-8.000623,"median":-7.590237,"eighty":-7.203617,"marketCap":763288470},{"date":"2026-03-27","current":-5.207658,"twenty":-7.991064,"median":-7.583871,"eighty":-7.203617,"marketCap":839224545},{"date":"2026-04-02","current":-5.640953,"twenty":-7.988887,"median":-7.541432,"eighty":-7.116384,"marketCap":909050820},{"date":"2026-04-10","current":-7.964495,"twenty":-7.986054,"median":-7.516065,"eighty":-6.867043,"marketCap":1283494221},{"date":"2026-04-17","current":-7.720766,"twenty":-7.972363,"median":-7.507481,"eighty":-6.969974,"marketCap":1244216941},{"date":"2026-04-24","current":-7.883252,"twenty":-7.986054,"median":-7.516065,"eighty":-7.077626,"marketCap":1270401794},{"date":"2026-05-01","current":-8.966125,"twenty":-8.009111,"median":-7.554503,"eighty":-7.116384,"marketCap":1444908993},{"date":"2026-05-08","current":-8.214962,"twenty":-8.052399,"median":-7.590237,"eighty":-7.121808,"marketCap":1323857628},{"date":"2026-05-15","current":-6.658186,"twenty":-8.072823,"median":-7.605091,"eighty":-7.121808,"marketCap":1328174850},{"date":"2026-05-22","current":-6.655912,"twenty":-8.056678,"median":-7.585993,"eighty":-6.867043,"marketCap":1327721393},{"date":"2026-05-29","current":-6.769572,"twenty":-8.053247,"median":-7.547968,"eighty":-6.753265,"marketCap":1350394231},{"date":"2026-06-05","current":-6.842314,"twenty":-8.050011,"median":-7.507675,"eighty":-6.705014,"marketCap":1364904847},{"date":"2026-06-12","current":-6.899144,"twenty":-8.036085,"median":-7.484139,"eighty":-6.662816,"marketCap":1376241266},{"date":"2026-06-18","current":-6.64,"twenty":-8.014204,"median":-7.474515,"eighty":-6.654094,"marketCap":1324547195},{"date":"2026-06-26","current":-7.265128,"twenty":-8.003169,"median":-7.454432,"eighty":-6.652876,"marketCap":1449247804},{"date":"2026-07-02","current":-8.201684,"twenty":-8.01675,"median":-7.469285,"eighty":-6.653639,"marketCap":1636071990},{"date":"2026-07-10","current":-9.047313,"twenty":-8.054945,"median":-7.484139,"eighty":-6.655912,"marketCap":1804757904},{"date":"2026-07-17","current":-8.460828,"twenty":-8.122848,"median":-7.507675,"eighty":-6.658186,"marketCap":1687766060},{"date":"2026-07-24","current":-8.008463,"twenty":-8.137812,"median":-7.547968,"eighty":-6.662732,"marketCap":1597528165},{"date":"2026-07-31","current":-3.189291,"twenty":-8.129236,"median":-7.516065,"eighty":-6.653448,"marketCap":636199834},{"date":"2026-08-07","current":-3.018802,"twenty":-8.123697,"median":-7.486261,"eighty":-6.561799,"marketCap":602190577},{"date":"2026-08-14","current":-2.692276,"twenty":-8.099082,"median":-7.474515,"eighty":-6.526795,"marketCap":537055294},{"date":"2026-08-21","current":-2.266153,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"marketCap":520823053},{"date":"2026-08-28","current":-3.032366,"twenty":-8.06605,"median":-7.420317,"eighty":-6.349031,"marketCap":696919516},{"date":"2026-09-04","current":-3.177455,"twenty":-8.055812,"median":-7.370362,"eighty":-6.26295,"marketCap":730264947},{"date":"2026-09-11","current":-3.333426,"twenty":-8.052399,"median":-7.329236,"eighty":-6.1487,"marketCap":766111286}],"updateTime":1789414415267},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654500961","title":"MapLight Therapeutics price target lowered to $24 from $43 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2654500961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654500961?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:20","pubTimestamp":1785237629,"startTime":"0","endTime":"0","summary":"Canaccord lowered the firm’s price target on MapLight Therapeutics (MPLT) to $24 from $43 and keeps a Buy rating on the shares. The firm updated it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-lowered-to-24-from-43-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-lowered-to-24-from-43-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006677","title":"MapLight downgraded to Equal Weight from Overweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006677?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:56","pubTimestamp":1785236218,"startTime":"0","endTime":"0","summary":"Morgan Stanley downgraded MapLight Therapeutics (MPLT) to Equal Weight from Overweight with a price target of $21, down from $34. While the ZEPHYR ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-downgraded-to-equal-weight-from-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-downgraded-to-equal-weight-from-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654058910","title":"MapLight Therapeutics is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2654058910","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654058910?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:28","pubTimestamp":1785234480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654071164","title":"U.S. Research Roundup- BioLife Solutions, Gossamer Bio, Intuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071164","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654071164?lang=en_us&edition=fundamental","pubTime":"2026-07-28 15:31","pubTimestamp":1785223918,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, IntuitJuly 28 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BioL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nL4N43U0K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRBR","BY","CBOE","FFIV","HUT","GDX","HAPN","HCA","CLSK","FMBH","LW","AGYS","CIFR","STCE","NEE","CHMG","GTY","WDGF","CHRW","IDU","PPA","HBT","BLFS","CDNS","GSHD","IP","HRB","ENSG","CUT","INTU","BKR","FRPT","LMTS","PINE","DIPR","GOSS","MSBI","HIG","LMTL","OWL","BWFG","RNWZ","NEM","HTH","NVTS","LMT","OTIS","SRCE","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654078237","title":"Maplight Therapeutics Inc : Jefferies Cuts Target Price to $25 from $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2654078237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654078237?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:55","pubTimestamp":1785214549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U09I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654204494","title":"Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654204494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654204494?lang=en_us&edition=fundamental","pubTime":"2026-07-28 01:00","pubTimestamp":1785171618,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Syensqo SA/NV (SHBBF) and MapLight Therapeutics, Inc. (MPLT)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-syensqo-sa-nv-shbbf-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-syensqo-sa-nv-shbbf-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654801068","title":"MapLight's Schizophrenia Drug Fails Once-daily Test, Shares Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2654801068","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654801068?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:27","pubTimestamp":1785155262,"startTime":"0","endTime":"0","summary":"MapLight's schizophrenia drug fails once-daily test, shares plungeJuly 27 (Reuters)-MapLight TherapeuticsMPLT.Osaid on Monday its schizophrenia drug failed to show statistically significant symptom im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4N43T0VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711040.USD","LU1868836591.USD","LU0306807586.USD","IHE","LU1670710661.SGD","LU0432979614.USD","FTXH","LU1670710588.SGD","LU2125154778.USD","LU0868494617.USD","LU1670711123.USD","BK4588","LU1868836914.USD","LU1261432733.SGD","LU2242646821.SGD","LU0306806265.USD","LU0882574055.USD","BMY","LU0061475181.USD","IE00BJT1NW94.SGD","LU1093756168.USD","LU1718418525.SGD","LU2125154935.USD","LU1074936037.SGD","LU1868837136.USD","LU0456855351.SGD","IE0009355771.USD","LU1983299246.USD","BK4534","LU1430594728.SGD","LU2133065610.SGD","LU1868837300.USD","LU1323610961.USD","LU1883839398.USD","BK4559","BK4007","LU1571399168.USD","LU0321505868.SGD","LU0096364046.USD","LU0225284248.USD","IE00B2B36J28.USD","LU2360032135.SGD","LU1093756325.SGD","LU1585245621.USD","LU0267386448.USD","LU1032466523.USD","MPLT","IE00BFTCPJ56.SGD","LU1291159041.SGD","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017731","title":"Maplight Therapeutics Shares Drop 55.7% Premarket After Co Announces Mid-Stage Trial Results for Schizophrenia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654017731?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:12","pubTimestamp":1785154348,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4N43T0X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654012194","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2654012194","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654012194?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:39","pubTimestamp":1785152371,"startTime":"0","endTime":"0","summary":"STAK  shares were down 55% in Monday premarket trading after the earlier session's 602% rally.MapLight Therapeutics  stock was down 55% after the company said a phase 2 trial of ML-007C-MA in schizophrenia met its primary endpoint, demonstrating a significant reduction in severity of the condition versus placebo.Profusa  shares were down 18% after the company signed a non-binding term sheet to acquire a privately held commercial-stage diagnostics and toxicology testing company.Recon Technology  stock was down 15%, following the earlier session's 11.6% gain.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCON","BK4179","MPLT","BK4082","PFSA","BK4139","STAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014028","title":"MapLight Therapeutics announces topline results from ZEPHYR trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014028?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:16","pubTimestamp":1785150965,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (MPLT) announced topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist co-for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-announces-topline-results-from-zephyr-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-announces-topline-results-from-zephyr-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109391861.USD","LU0061474705.USD","MA","LU2360107671.USD","BK4534","IE00BN29S564.USD","LU2403377893.USD","STBQ","LU0127658192.USD","FDFF","FNCL","LU1815333072.USD","LU2764262908.HKD","SGXZ51526630.SGD","LU1691799644.USD","LU2023250504.SGD","LU0345769631.USD","LU0234570918.USD","LU1974910355.USD","LU2552382058.USD","BK4227","SG9999002232.USD","LU2361044865.SGD","LU1989772923.USD","LATR","SG9999011175.SGD","LU0170899867.USD","LU0912757837.SGD","LU0950375773.USD","LU0642271901.SGD","LU0198837287.USD","IPAY","LU0006306889.USD","LU2237957811.SGD","UYG","IE000SO60NU8.SGD","VFH","XLF","LU0353189680.USD","LU1629891620.HKD","MPLT","IYG","IE00BHPRN162.USD","LU1814569148.SGD","LU1861217088.USD","LU2506951875.HKD","SG9999000418.SGD","LU0868494708.USD","LU1280957306.USD","LU1868837300.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014558","title":"MapLight Says Phase 2 Zephyr Trial Shows Ml-007c-ma Cuts PANSS Score in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014558","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014558?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:02","pubTimestamp":1785150129,"startTime":"0","endTime":"0","summary":"MapLight says Phase 2 ZEPHYR trial shows ML-007C-MA cuts PANSS score in schizophreniaMapLight Therapeutics reported positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in adults with ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL3f19z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","NDAQ","BK4588","IE00BN0W2W23.USD","MPLT","IE00BN0W2V16.EUR","BK4585","BK4139","SG9999014005.SGD","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","BCDF","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654143780","title":"Maplight Therapeutics - to Proceed with Additional Registrational Trial and Engage FDA at End-of-Phase 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2654143780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654143780?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654142010","title":"Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2654142010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654142010?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014822","title":"Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014822?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014373","title":"Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014373?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014340","title":"Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014340?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654601468","title":"MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654601468","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654601468?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":"The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to place","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333379/0/en/MapLight-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-ZEPHYR-Trial-of-ML-007C-MA-in-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BID","LU0823417653.USD","LATR","LU0107464264.USD","LU1718418525.SGD","MPLT","LU0056508442.USD","ASD","LU2077746001.SGD","LU2092627202.USD","LU0823421333.USD","BK4139","LU2506951958.HKD","BK4527","LU2092937148.SGD","LU2420271590.USD","XLF","IE00B4JS1V06.HKD","IYG","LU0642271901.SGD","STBQ","LU1316542783.SGD","LU0823421416.USD","BK4585","VFH","MA","UYG","LU1868836914.USD","LU0557290698.USD","IE000WAW04H5.SGD","IPAY","SG9999003800.SGD","LU0061475181.USD","FNCL","LU2360107671.USD","IE00BKDWB100.SGD","LU1280957306.USD","LU0823434583.USD","LU2168564149.EUR","LU0708995401.HKD","LU1861217088.USD","LU2168563687.JPY","LU1712237335.SGD","LU1983260115.SGD","FDFF","LU1732800096.USD","BK4533","LU1815333072.USD","LU0096362180.USD","LU0210533765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654098633","title":"MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2654098633","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654098633?lang=en_us&edition=fundamental","pubTime":"2026-07-27 08:26","pubTimestamp":1785111993,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (MPLT) has drawn investor attention recently as its clinical-stage central nervous system pipeline, including candidates for schizophrenia, Alzheimer’s disease psychosis and Parkinson’s disease, trades around $36.56 with a market value near $1.66 billion.\nSee our latest analysis for MapLight Therapeutics.\nFor context, MapLight Therapeutics’ share price return has been strong over 2024, with a year to date gain of 118.01% and a 90 day share price return of 19.32%...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/maplight-therapeutics-mplt-rally-puts-its-cns-story-and-valu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/maplight-therapeutics-mplt-rally-puts-its-cns-story-and-valu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MPLT","BK4139","CNS","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653308984","title":"MapLight Therapeutics price target raised to $43 from $35 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2653308984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653308984?lang=en_us&edition=fundamental","pubTime":"2026-07-24 18:50","pubTimestamp":1784890228,"startTime":"0","endTime":"0","summary":"Canaccord analyst Sumant Kulkarni raised the firm’s price target on MapLight Therapeutics (MPLT) to $43 from $35 and keeps a Buy rating on the shar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-43-from-35-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-43-from-35-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653701014","title":"U.S. Research Roundup-deckers Brands, Rollins, United Rentals","url":"https://stock-news.laohu8.com/highlight/detail?id=2653701014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653701014?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:14","pubTimestamp":1784877253,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United RentalsJuly 24 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Decker","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4N43Q0HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MOH","AMDS","BPOP","ROL","EW","CHPS","ACI","PNFP","LRCX","AMAT","LMT","AMUU","MBWM","NSC","DOV","TINY","SETM","DECK","MEDP","NVR","AMP","AAL","ALK","JUP.UK","DOMO","CMCSA","HON","NIC","KRMN","MISL","SAM","INTC","CTSH","GPZ","BX","FCX","THRM","FOA","PKG","R","LOB","NDAQ","FCNCA","OBK","TEK","EMET","DFTX","AMD","MPLT","DOW"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":126,"code":"91000000","status":"200"}]}}